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LETTER TO EDITOR
Cell cycle progression score as a predictive biomarker for
overall survival in patients with adrenocortical carcinoma
Dear Editor,
Following the report by Cuzick et al on prognostic value
of an established cell cycle progression score (CCPS) in
prostate cancer,1 many studies have validated CCPS in
further independent prostate cancer cohorts.2 Similarly,
Cruzick’s CCPS was found to predict mortality in other
urological malignancies such as kidney cancer.3
The score is calculated upon the relative expression
levels of 31 selected CCP genes normalized to 15 house-
keeper genes using quantitative RT-PCR. However, in this
method some shortcomings are inevitable: First, these
31 genes, selected from a set of documented CCP genes
using Pearson’s correlation coefficient, have been disputed
to comprehensively represent the hallmark of cell cycle
progression. Second, the results of quantitative RT-PCR
are susceptible to considerable variability, including dif-
ferent RNA extraction methods, inconsistent human oper-
ations, and heterogeneous samples quality in repeated
experiments. In the current study, we aimed to overcome
these shortcomings, and have evaluated a novel method in
patient cohorts with adrenocortical carcinoma (ACC).
In this study, single sample gene set enrichment
analysis (ssGSEA)4 was performed to quantify CCP
along with some other cancer-related hallmarks such as
“epithelial–mesenchymal transition (EMT),” “angiogen-
esis,” and “hypoxia,” based on corresponding gene sets
retrieved from Molecular Signatures Database (MSigDB)5
and RSEM-normalized RNA-seq data of 79 ACC samples
from The Cancer Genome Atlas (TCGA).6 Cibersort was
used to quantify the immune infiltration based on the gene
expression profile.7 Z-score method was used to normal-
ize both ssGSEA and immune infiltration scores. Distance
between different hallmarks was depicted using hierarchi-
cal clustering analysis. Cox proportional-hazards model
was used to evaluate the importance of each hallmark
for overall survival (OS). Clinical phenotype and somatic
mutation data were used to depict relationships between
ssGSEA-derived CCPS and different clinicopathological
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features. One-way analysis of variance (ANOVA) was per-
formed to evaluate the difference of CCPS in different
tumor stages. Kaplan-Meier curve was plotted, and log-
rank test was used to evaluate survival difference between
CCPS-low and CCPS-high group. Multivariate Cox regres-
sion analysis was performed to identify independent risk
factors for OS among various clinicopathological variables
including CCPS, age, gender, pathological T (pT) stage,
pathological N (pN) stage, clinical M (cM) stage, and sur-
gical margin (SM) status. Furthermore, the predictive per-
formances of each parameter were compared at differ-
ent time points in the follow-up using time-dependent
receiver operating characteristic (tROC) with R package
“survivalROC.”8
Distance between the nine cancer-related hallmarks
was shown in the cluster dendrogram in Figure 1A. We
observed that CCP and “DNA repair” remain close to
each other but distant to other hallmarks. Among var-
ious cancer-related hallmarks, CCP exhibited the most
powerful risk for OS (Figure 1B). The overview of rela-
tionships between CCPS and clinicopathological features
demonstrated that CCPS was significantly correlated with
factors considered to be associated with a more aggres-
sive behavior such as heavy mutation burden, advanced
tumor stages and worse clinical outcomes (Figure 1C, left
panel). Considering cell cycle process being tightly cor-
related with tumor growth, we focused further investiga-
tion on the expression profile in different pT stages. As
expected, CCPS was significantly and stepwisely elevated
inmore advanced pT stages (P= 1.01× 10-5; Figure 1C, right
panel). Using the median as cutoff value, patients with
higher CCPS exhibited significantly worse OS (HR= 12.91,
95% CI= 6.047-27.57, P= 4.05× 10-8; Figure 1D).Multivari-
ate Cox regression analysis demonstrated that only CCPS
serves as an independent risk factor for OS among various
clinicopathological features (HR = 4.721, 95% CI = 2.017-
11.05, P = 3.48e-4; Figure 1E). In addition, tROC analy-
sis indicated that CCPS can serve as a more powerful and
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F IGURE 1 CCPS serves as a powerful risk factor and a promising predictor for OS in ACC. A, Cluster dendrogram depicts the dis-
tance between different hallmarks. B, Among various cancer-related hallmarks, CCP is the strongest risk factor for overall survival in ACC.
C, Overview of relationships between CCPS and clinicopathological features. Annotations: F, female; M, male; L, left; R, right; SM, surgical
margin; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; A, alive; D, deceased; NA, not available. D, Patients with higher CCPS exhibited significantly worse prognosis. Annotations: CCPS-L,
CCPS-low; CCPS-H, CCPS-high. E, Multivariate Cox regression analysis demonstrated that CCPS served as an independent risk factor for over-
all survival among various clinicopathological features. F, Results of tROC analysis demonstrated that CCPS served as a powerful and consistent
predictor for overall survival in a long-term follow-up
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consistent predictor for OS in a long-term follow-up, in
comparison to other traditional prognostic parameters
(Figure 1F).
In the current analysis, ssGSEA algorithm was used
to quantify CCP. ssGSEA calculates separate enrichment
scores for each pairing of a sample and gene set, thereby
representing the degree to which the genes in a particular
gene set are coordinately up- or down-regulated within a
sample.4 Based on these data, the ssGSEA-derived CCPS
serves as a powerful risk factor and a promising predictor
for OS in ACC. Although this method seems robust and
effective, validation in more studies, especially in prospec-
tively designed trials, is warranted.
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